Search
Esomeprazole
go.drugbank.com/drugs/DB00736ApprovedInvestigationalEsomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme … increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.
International brands: ES-ODProducts: E-SOME, ESOMEPRAZOLO EGKetorolac
go.drugbank.com/drugs/DB00465ApprovedInvestigationalKetorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.
Products: KETOROLAC EGCephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Synonyms: (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidProducts: LUPICEFF ER, CEFALON ® EROsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideApixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Products: APIXABAN EGLevocetirizine
go.drugbank.com/drugs/DB06282ApprovedInvestigational[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Products: LEVOCETIRIZINA EGCeftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalCeftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges , eyes , and inner ear . Ceftriaxone has broader and strong...
Products: CEFTRIAXONE EG, ROCEPHIN 1 GR IM ENJ. COZ. HAZ. ICIN TOZ ICEREN FLAKONValsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigational[A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States. … [A174157,A174160,A174163] Improvements in chronic kidney disease with valsartan include both clinically and statistically significant decreases in urinary albumin and protein excretion in patients diagnosed
Mixtures: VALSARTAN E IDROCLOROTIAZIDE EG, VALSARTAN E IDROCLOROTIAZIDE EGCategories: Agents Acting on the Renin-Angiotensin SystemPemivibart
go.drugbank.com/drugs/DB18720InvestigationalPemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. … [L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728]
Simvastatin
go.drugbank.com/drugs/DB00641ApprovedInvestigational[A181087, A181406] Simvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line … clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%.
Mixtures: EZETIMIBE E SIMVASTATINA EG, EZETIMIBE E SIMVASTATINA EGProducts: SIMVASTATINA EG